Leire Recalde‐Percaz

Universitat de Barcelona — Spain

Biochemistry, Genetics and Molecular Biology · Life Sciences

5h-index227citations33works2.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Fibroblast Growth Factor Research(19), Cancer Cells and Metastasis(17), Cancer, Hypoxia, and Metabolism(10), Axon Guidance and Neuronal Signaling(7), Cancer, Stress, Anesthesia, and Immune Response(7)

Publications33 total

Neuropilin-2 upregulation by stromal TGFβ1 induces lung disseminated tumor cells dormancy escape and promotes metastasis outgrowth
Neoplasia·2025Open Access
Neuropilin-2 Upregulation by Stromal Tgfβ1 Induces Lung Disseminated Tumor Cells Dormancy Escape and Promotes Metastasis Outgrowth
SSRN Electronic Journal·2025Open Access
Role of semaphorins, neuropilins and plexins in cancer progression
Cancer Letters·2024· 12 citedOpen Access
The SEMA3F-NRP1/NRP2 axis is a key factor in the acquisition of invasive traits in in situ breast ductal carcinoma
Breast Cancer Research·2024· 2 citedOpen Access
The SEMA3F-NRP1/NRP2 axis is a key factor in the acquisition of invasive traits in in situ breast ductal carcinoma 
2024Open Access
Supplementary Figure S4 from Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation
2023Open Access
Supplementary Legend from Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation
2023Open Access
Supplementary Figure S5 from Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation
2023Open Access
Supplementary Legend from Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation
2023Open Access
Supplementary Figure S6 from Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation
2023Open Access
Supplementary Figure S2 from Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation
2023Open Access
Supplementary Material and methods from Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation
2023Open Access
Data from Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation
2023Open Access
Supplementary Figure S2 from Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation
2023Open Access
Supplementary Figure S4 from Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation
2023Open Access
Supplementary Figure S1 from Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation
2023Open Access
Supplementary Figure S6 from Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation
2023Open Access
Supplementary Figure S5 from Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation
2023Open Access
Supplementary Figure S3 from Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation
2023Open Access
Supplementary Figure S3 from Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation
2023Open Access
page 1 of 2Next →

Frequent Co-authors

Gemma Fuster(32), Aleix Noguera‐Castells(31), Paloma Bragado(30), Patricia Fernández‐Nogueira(29), Anna López‐Plana(29), Núria Moragas(29), Pere Gascón(27), Mario Mancino(26), Patricia Jáuregui(24), Estel Enreig(22), Raúl Alonso(21), Elisabet Ametller(20), Vanesa Almendro(19), Sílvia Menéndez(19), Federico Rojo(19), Anke Bill(19), L. Alex Gaither(19), Laia Serrano(19), Ana Rovira(19), Aňa Lluch(19)